WO2023167563A1 - Composition contenant de l'acide n-carbamyl-l-glutamique pour le traitement de maladies inflammatoires - Google Patents

Composition contenant de l'acide n-carbamyl-l-glutamique pour le traitement de maladies inflammatoires Download PDF

Info

Publication number
WO2023167563A1
WO2023167563A1 PCT/KR2023/002981 KR2023002981W WO2023167563A1 WO 2023167563 A1 WO2023167563 A1 WO 2023167563A1 KR 2023002981 W KR2023002981 W KR 2023002981W WO 2023167563 A1 WO2023167563 A1 WO 2023167563A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbamyl
intestinal
glutamic acid
ncg
strain
Prior art date
Application number
PCT/KR2023/002981
Other languages
English (en)
Korean (ko)
Inventor
손미영
박두상
이하나
최은호
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2023167563A1 publication Critical patent/WO2023167563A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/14—Glutamic acid; Glutamine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • It relates to a method for biosynthesis of N-carbamyl-L-glutamic acid and its use for treatment of inflammatory diseases.
  • N-carbamyl-L-glutamic acid is a metabolically stable analogue of N-acetylglutamate that activates carbamyl phosphatase-1, the first enzyme involved in the urea cycle. am. NCG is nontoxic to animals and infants and readily penetrates cells and mitochondria. NCG intake has been reported to increase the length of villi or the depth of crypts in the jejunum of immature baby animals. In fact, studies have reported that NCG is used as an important feed additive for dairy cows, beef cattle, and newborn pigs to increase milk production, increase pregnancy rate, reduce morbidity and mortality, and increase birth weight and growth rate.
  • the large intestine is an organ present at the highest end of the digestive system and is known to play a role in absorbing water, vitamins, minerals, and the like.
  • various diseases such as colon cancer, colon polyps, irritable bowel syndrome, ulcerative colitis, and Crohn's disease are induced due to genetic and environmental factors.
  • ulcerative colitis is a chronic inflammatory bowel disease that causes excessive inflammation in the large intestine, resulting in symptoms such as diarrhea, lower abdominal pain, abdominal distension, and bloody stools. Ulcerative colitis is classified into chronic and acute according to the duration of onset, and into infectious and non-infectious according to the cause. In this disease, inflammation first occurs in the rectal area, the barrier collapses, pathogenic bacteria and intestinal bacteria invade the body, and the immune response occurs excessively, extending its scope to the first half of the large intestine. Ulcerative colitis patients have a 10 to 20 times higher risk of colorectal cancer than normal patients, and the risk increases as the duration of the disease and the area of the site increase.
  • ulcerative colitis is a disease that cannot be cured after onset. Ulcerative colitis patient groups are largely divided into mild, moderate, and severe stages, and standard treatment for each stage is required.
  • 5-aminoslicylic acid (5-ASA) preparations are used for the treatment of mild and moderate patients with ulcerative colitis, 20 to 40% of patients have no therapeutic effect or side effects occur, so new treatments and usage methods development is needed Until now, research on the cause of onset and treatment has been conducted using various animal models, but the cause of onset of inflammatory bowel disease, especially ulcerative colitis, has various and complex characteristics, making it difficult to develop a cure. Therefore, it is necessary to develop an alternative treatment that can overcome the side effects and limitations of existing treatments.
  • NCG can be biosynthesized using Lactobacillus reuteri DS0384, and NCG is effective as a therapeutic agent for ulcerative colitis. It was confirmed that the present invention was completed.
  • One object of the present invention is to provide a method for biosynthesizing N-carbamyl-L-glutamic acid.
  • Another object of the present invention is to provide a novel use of N-carbamyl-L-glutamic acid for prevention or treatment of inflammatory bowel disease.
  • Another object of the present invention is to provide a suitable usage method using the composition.
  • the present invention provides a method for producing N-carbamyl-L-glutamic acid, including culturing the Lactobacillus reuteri DS0384 strain.
  • compositions for preventing, improving or treating inflammatory diseases comprising N-carbamyl-L-glutamic acid as an active ingredient.
  • the composition may be a pharmaceutical composition, health functional food composition or feed composition.
  • N-carbamyl-L-glutamic acid which had to be produced by conventional chemical methods, can be biosynthesized by culturing Lactobacillus reuteri DS0384 strain.
  • N-carbamyl-L-glutamic acid which was an active ingredient.
  • N-carbamyl-L-glutamic acid has a therapeutic effect on inflammatory bowel disease by improving histological lesions and reducing inflammatory markers in inflammatory bowel disease animal models. identified. In addition, it was confirmed that the incidence of inflammatory bowel disease was reduced in an animal model administered with N-carbamyl-L-glutamic acid, thereby having a preventive effect against inflammatory bowel disease.
  • composition comprising N-carbamyl-L-glutamic acid as an active ingredient of the present invention can be usefully used as pharmaceuticals, foods, and feeds for the prevention, improvement, or treatment of ulcerative colitis among inflammatory bowel diseases, and thus the related industry very useful for
  • an appropriate usage method capable of exhibiting a therapeutic effect on inflammatory bowel disease is identified, and the therapeutic effect of N-carbamyl-L-glutamic acid on inflammatory bowel disease is confirmed by using the composition or administration method of the present invention. can be maximized.
  • Panel a of Figure 1 shows B. longum, Lactobacillus gasseri (L. gasseri), Lactobacillus curvatus (L. curvatus), Lactobacillus rhamnosus (L. rhamnosus) and the present invention.
  • Lactobacillus reuteri DS0384 L. reuteri
  • morphological changes in intestinal organoids were confirmed under a microscope (upper data, Bright field, BF) and immunofluorescence staining of the mature intestinal tract. It is the result (lower data) shown by comparing the expression of the marker protein. Scale bars are 500 ⁇ m in black and 100 ⁇ m in white.
  • Panel b of FIG. 1 shows B.
  • Panel a of FIG. 2 shows intestinal organoids treated with cultures of DS0191, DS0195, DS0333, DS0354 and Lactobacillus reuteri DS0384 strains classified as Lactobacillus reuteri, and then morphological changes in intestinal organoids were confirmed under a microscope.
  • the result (upper data, Bright field, BF) and the result (lower data) shown by comparing the expression of the mature intestinal marker protein through immunofluorescence staining. Scale bars are 500 ⁇ m in black and 100 ⁇ m in white.
  • Panel b of FIG. 2 is a graph comparing the expression levels of mature intestinal marker genes (CDX2, DPP4, OLFM4, DEFA5, CREB3L3, KRT20, LYZ, LCT, SLC5A1 and MUC13) by qRT-PCR.
  • Panel a of FIG. 3 is a result of microscopically confirming the morphological changes of intestinal organoids after treating the culture solution of DSP007, DS0337, KCTC3594 and Lactobacillus reuteri DS0384 strains of the present invention classified as Lactobacillus reuteri to intestinal organoids ( Upper data, Bright field, BF) and immunofluorescence staining show the results of comparing the expression of mature intestinal marker proteins (lower data). Scale bars are 500 ⁇ m in black and 100 ⁇ m in white.
  • Panel b of FIG. 3 is a graph comparing the expression levels of mature intestinal marker genes (CDX2, DPP4, OLFM4, DEFA5, CREB3L3, KRT20, LYZ, LCT, SLC5A1 and MUC13) by qRT-PCR.
  • Figure 4 shows the morphological changes of intestinal organoids (scale bar: 500 ⁇ m, Upper panel) and a graph comparing the expression patterns of intestinal maturation marker genes in intestinal organoids treated with the culture solution of the Lactobacillus reuteri strain obtained for each culture time by qRT-PCR (middle panel).
  • a graph comparing the size change of the intestinal organoid by surface area and the number of budding structures of the intestinal organoid is compared (lower panel).
  • FIG. 5 is a heat map showing metabolites contained in the Lactobacillus reuteri DS0384 strain culture medium using capillary electrophoresis mass spectrometry, and 14 metabolites not appearing in the KCTC3594 strain are marked in red.
  • Panel a of FIG. 6 shows the intestinal maturation and intestinal development effects of 7 metabolites that are differentially included in the culture medium of the Lactobacillus reuteri DS0384 strain compared to the same strain, and the morphological changes of intestinal organoids are examined under a microscope. The results confirmed by (upper data, Bright field, BF) and the results shown by comparing the expression of mature intestinal marker proteins through immunofluorescence staining (lower data), and panel b of FIG. 6 shows mature intestinal marker genes (CDX2, DPP4, OLFM4, DEFA5, CREB3L3, KRT20, LYZ, LCT, SLC5A1 and MUC13) gene expression patterns were confirmed through qRT-PCR and compared.
  • Figure 7 shows the result of microscopically confirming the morphological changes of intestinal organoids (left data, Bright field, BF) and immunofluorescence staining that NCG promotes intestinal maturation and intestinal development at a level similar to that of the culture medium of Lactobacillus reuteri DS0384 strain. This is the result (data on the right) shown by comparing the expression of the mature intestinal marker protein through .
  • Figure 8 shows that NCG promotes intestinal maturation and intestinal development at a level similar to that of the culture medium of Lactobacillus reuteri DS0384 strain.
  • a graph confirming the number of structures (upper panel) and a result of comparing the expression patterns of intestinal maturation markers by qRT-PCR (lower panel).
  • Figure 9a is a schematic diagram of an intestinal organoid experiment to confirm the protective efficacy of NCG from ulcerative colitis.
  • Representative pro-inflammatory cytokines (Ifn ⁇ , Tnf ⁇ ; I/T) of ulcerative colitis were treated to induce intestinal organoids similar to intestinal inflammation. It shows an experiment in which the phenotype of intestinal organoid epithelial cells was observed by simultaneous treatment with NCG.
  • 9B shows morphological changes of normal intestinal organoids, colitis-like intestinal organoids, and NCG-treated intestinal organoids in an experiment to confirm the intestinal protective effect of NCG against ulcerative colitis.
  • 9C is a comparison of changes in the size of intestinal organoids (left panel) and changes in the number of germinated structures (right panel) in order to confirm morphological changes in colitis-like intestinal organoids and NCG-treated intestinal organoids. It is a graph
  • 9D shows goblet cells secreting mucin through histological morphology analysis (H&E staining) and mucin staining (Alcian Blue-Periodic Acid Schiff staining; AB-PAS staining) of colitis-like intestinal organoids and NCG-treated intestinal organoids. This is the result of confirming the intestinal function.
  • FIG. 9e confirms through immunofluorescence staining that the barrier function (ZO-1) is restored and intestinal stem cell proliferating cells (Ki67) are not reduced compared to colitis-like intestinal organoids through NCG co-treatment (left panel). ).
  • FIG. 9F shows, at the gene level, pro-inflammatory cytokines (IL-1 ⁇ , IL-6, IL-8, TNF ⁇ ), intestinal epithelial cells and structures (VIL1, EPCAM, KRT20), barrier structures (CLAUDIN), and goblet cells (MUC2). ), and the expression patterns of Panes cells (LYZ) were confirmed and compared through qRT-PCR.
  • pro-inflammatory cytokines IL-1 ⁇ , IL-6, IL-8, TNF ⁇
  • VIL1, EPCAM, KRT20 intestinal epithelial cells and structures
  • CLAUDIN barrier structures
  • MUC2 goblet cells
  • Figure 10a is a schematic diagram of an experiment to confirm the efficacy of NCG preventing or protecting the intestines from ulcerative colitis. An experiment in which the disease phenotype was observed by inducing ulcerative colitis after treatment with NCG to confirm the efficacy of preventing or protecting the intestine from ulcerative colitis is shown.
  • Figure 10b shows the weight loss rate of a normal group, an ulcerative colitis control group, and an NCG-treated experimental group in an experiment to confirm the efficacy of NCG for preventing ulcerative colitis or protecting the intestines.
  • 10c is a result showing the length and fecal shape of the large intestine of a normal group, an ulcerative colitis control group, and an NCG experimental group in an experiment to confirm the efficacy of NCG for preventing or protecting the intestine from ulcerative colitis.
  • Figure 10d is a graph showing changes in the length of the large intestine by a normal group, an ulcerative colitis control group, and NCG treatment in an experiment to confirm the efficacy of preventing or protecting the intestines from NCG ulcerative colitis.
  • Figure 10e shows the results of histological analysis of a normal group, an ulcerative colitis control group, and an NCG experimental group in an experiment to confirm the efficacy of NCG for preventing or protecting the intestine from ulcerative colitis.
  • Figure 11a is a schematic diagram of an experiment to confirm the therapeutic efficacy of NCG for ulcerative colitis, showing an experiment in which a mouse model induced with ulcerative colitis was treated with NCG for 10 days and the disease phenotype was observed.
  • Figure 11b shows the weight loss rate of a normal group, an ulcerative colitis control group, and an NCG treatment experimental group in an experiment to demonstrate the efficacy of NCG enteritis treatment.
  • 11c is a photograph confirming the length and fecal shape of the large intestine of a normal group, an ulcerative colitis control group, and an NCG experimental group in an experiment to demonstrate the efficacy of NCG for treating enteritis.
  • Figure 11d is a graph showing changes in the length of the large intestine by NCG treatment in a normal group, an ulcerative colitis control group, and an experiment to demonstrate the efficacy of NCG for treating enteritis.
  • Figure 12b is a graph quantifying histological morphology analysis of a cross-section of the large intestine in an experiment to show the efficacy of NCG enteritis treatment.
  • Figure 12c is an experiment to show the efficacy of NCG enteritis treatment, mucin staining (Alcian Blue-Periodic Acid Schiff staining; AB-PAS staining) confirms the reduction of mucin-secreting goblet cells and intestinal functionality.
  • mucin staining Alcian Blue-Periodic Acid Schiff staining; AB-PAS staining
  • 12D shows the results of MUC2 immunofluorescence staining, and it was confirmed that goblet cells appeared at a level similar to that of the normal group in the 100 mM NCG-treated group compared to the ulcerative colitis control group.
  • Figure 14a confirms the inflammatory markers (inflammatory cytokines, immune cell infiltration) of the normal group, the ulcerative control group, and the NCG treatment experimental group. It shows the result of immunofluorescence staining to confirm secretion and infiltration of immune cells (myeloid cells; CD11b+, macrophages; F4/80+).
  • 14b is a diagram confirming the expression of pro-inflammatory cytokines (Il-6, Il-1 ⁇ , Tnf ⁇ , Il-17a) and the nitric oxide indicator iNos at the gene level.
  • Figure 15a confirms that DSS-induced inflammatory bowel disease is alleviated to the level of the normal group through 100 mM NCG treatment at the gene level.
  • the Spearman's correlation coefficient of the genomes of the normal group, ulcerative colitis control group, and NCG experimental group It shows the result of analyzing a total of 21,823 genes by comparative analysis through correlation. Red indicates the highest similarity between samples, and blue indicates the lowest similarity between samples.
  • 15B is an analysis of the main components of differentially expressed genes (2-fold change) among the normal group, the ulcerative colitis control group, and the NCG experimental group, and shows the difference between each gene group through a PCA plot.
  • 15c shows data compared in gene expression levels of a normal group, an ulcerative colitis control group, and a 100 mM NCG experimental group as a pattern graph and a heat map.
  • 15D shows the results of GOterm analysis (biological process) of a total of 238 genes whose expression is decreased in the colitis control group (PBS) group compared to the normal group and whose expression is increased to the level of the normal group through 100 mM NCG treatment.
  • PBS colitis control group
  • 15E is a heat map representation of data comparing expression levels of genes involved in the Wnt signaling pathway.
  • FIG. 15F shows the results of comparing mRNA expression levels of major genes (Fzd7, Tcf7, Ror1, and Axin2) among genes involved in the Wnt signaling pathway through qPCR.
  • 15g is a result of comparing the expression of intestinal stem cell proliferation marker (Ki-67) through immunofluorescence chemical staining.
  • 15H shows the result of measuring the expression level of the Cps1 gene through RNAseq, and shows that NCG does not affect the expression level of Cps1, which is one of the indicators of ulcerative colitis.
  • Figure 16a is a schematic diagram of an experiment to confirm the effect of NCG in the normal group, showing an experiment in which PBS or NCG was orally administered to the normal group for 10 days, and clinical symptoms were observed and analyzed in the normal group.
  • Figure 16b shows the change in body weight of the normal group and the 100 mM NCG treated experimental group in an experiment to confirm the effect of NCG in the normal group.
  • 16c is a photograph confirming the length and fecal shape of the large intestine of the normal group and the 100 mM NCG treated experimental group in an experiment to confirm the effect of NCG in the normal group.
  • 16d shows the histological morphology of the intestine by H&E staining in the normal group and the 100 mM NCG treated experimental group in an experiment to confirm the effect of NCG in the normal group, and it was confirmed that the crypt and villous structure were maintained similarly to the normal group. .
  • Figure 16e is an experiment to confirm the effect of NCG in the normal group, the increase and decrease of mucin-secreting goblet cells and intestinal functionality were confirmed through AB-PAS staining of the normal group and the 100 mM NCG treated experimental group, similar to the normal group. In the experimental group treated with 100 mM NCG, it was confirmed that the goblet cell morphology and mucin secretion function were maintained.
  • Figure 16f compares the expression of pro-inflammatory cytokines (Il-6, Il-1 ⁇ , Tnf ⁇ , Ifn ⁇ , Il-17a) and inflammation-related enzymes (iNos) at the gene level in an experiment to confirm the effect of NCG in the normal group. It did
  • One aspect of the present invention provides a method for producing N-carbamyl-L-glutamic acid comprising the steps of culturing the Lactobacillus reuteri DS0384 strain in a medium.
  • N-carbamyl-L-glutamic acid (N-carbamyl-L-glutamic acid, NCG) is a metabolically stable form of N-acetylglutamate that activates carbamyl phosphate synthetase-1, the first enzyme involved in the urea cycle. As an analog, it has a structure of the following chemical formula.
  • the Lactobacillus reuteri may be strain DS0384, and may be deposited at the Korea Research Institute of Bioscience and Biotechnology (KCTC) on April 6, 2020 under accession number KCTC 14164BP.
  • the Lactobacillus reuteri DS0384 strain is a microorganism classified in the genus Lactobacillus, and may be a microorganism that is not toxic or does not cause disease in humans or non-human animals, and is beneficial to the health of humans or non-human animals in the intestine. It can act as a beneficial bacteria.
  • the Lactobacillus reuteri DS0384 strain may have an activity to promote intestinal development or intestinal maturation and restore intestinal damage.
  • the development of the small intestine and large intestine is achieved even when mice are given oral gavage with a culture solution containing cells of the Lactobacillus reuteri DS0384 strain or a culture solution containing metabolites produced by the strain. It was confirmed that the expression of the mature intestinal marker gene was increased.
  • the Lactobacillus reuteri DS0384 strain exhibited an intestinal maturation promoting effect that was not shown in other lactic acid bacteria, and was related to intestinal maturation even when compared to the case of treating 7 types of microbial cultures classified as Lactobacillus reuteri. It was confirmed that the expression level of genes and proteins was significantly higher, or the expression of intestinal maturation-related marker genes, which were not increased in other microbial culture medium treatment groups, was increased (FIGS. 1 to 3).
  • the culture solution of the Lactobacillus reuteri DS0384 strain contains N-carbamyl-L-glutamic acid, a metabolite produced by the strain.
  • N-carbamyl-L-glutamic acid was included among 14 metabolites present only in the culture medium of Lactobacillus reuteri DS0384 among five homologous Lactobacillus reuteri strains.
  • N-carbamyl-L-glutamic acid was the active ingredient showing the effect of promoting intestinal maturation and development of the culture medium of the Lactobacillus reuteri DS0384 strain, since only this has the effect of promoting intestinal maturation and development at the same level as the culture medium ( 5 and 6).
  • the culture medium refers to the culture medium itself obtained by culturing the strain, the culture supernatant obtained by removing the strain therefrom, and their filtrate, concentrate or dried product, "culture supernatant", “conditioned culture medium” Or it may be used interchangeably with “conditioned medium”.
  • the culture medium is obtained by culturing the Lactobacillus reuteri DS0384, and may be the culture medium itself containing the cells of the strain, or the culture supernatant obtained by removing the cells therefrom, and also their filtrate, It can be a concentrate or dry matter.
  • the culture medium from which the cells are removed may contain components produced and secreted by the Lactobacillus reuteri DS0384 strain, such as metabolites, and thus may have intestinal development or intestinal maturation activity, and preventive or therapeutic activity of inflammatory diseases.
  • the filtrate is obtained by removing solid particles suspended from the culture solution of Lactobacillus reuteri DS0384 to obtain only the water-soluble supernatant excluding the precipitate, and the particles are filtered out using a filter such as cotton or nylon, such as a filter of 0.2 ⁇ m to 5 ⁇ m, or Freezing filtration, centrifugation, etc. may be used, but is not limited thereto.
  • the concentrate increases the solid concentration of the culture solution, and may be a concentrate of the culture solution containing the lactic acid bacteria cells or a concentrate of the culture supernatant from which the lactic acid bacteria cells are removed.
  • the concentrate may be concentrated by vacuum concentration, plate type concentration, thin film concentration, etc., but is not limited thereto.
  • the content of the culture medium included in the composition of the present invention may be appropriately adjusted according to the concentration of the concentrate.
  • the culturing may be performed in a medium for culturing a Lactobacillus strain in general.
  • the medium may contain components essential for the growth of the Lactobacillus reuteri DS0384 strain.
  • the Lactobacillus reuteri DS0384 strain may include components such as glucose, amino acid, yeast extract, proteus peptone, polysorbate 80, ammonium citrate, magnesium sulfate, dipotassium phosphate, and sodium acetate, but is not limited thereto, and the Lactobacillus reuteri DS0384 strain It can be included without limitation as long as it is a component that can help the growth of.
  • the pH of the medium may be adjusted to the range of pH 5 to 7.
  • the culturing may be performed for 3 hours or more, 5 hours or more, 7 hours or more, 10 hours or more, 13 hours or more, 15 hours or more, 18 hours or more, 20 hours or more, 24 hours or more, specifically 18 hours or more It can be.
  • the method for producing the N-carbamyl-L-glutamic acid may further include separating the culture solution of the strain.
  • the step of separating the culture medium of the strain refers to the step of separating the cells of the strain cultured in the medium and the metabolites produced by the strain. Obtaining only the culture supernatant excluding the precipitate by removing solid particles floating in the culture itself cultured in the medium, and centrifuging or filtering the strain and its culture medium. Concentrating the culture supernatant obtained by the separation steps may be included.
  • the method for producing N-carbamyl-L-glutamic acid may further include purifying N-carbamyl-L-glutamic acid from the culture medium of the strain.
  • the purification is a method of purifying a conventional microbial culture solution by removing impurities from a mixture of a strain and a culture solution or a culture solution separated from the strain, and separating N-carbamyl-L-glutamic acid into functional raw materials or raw materials. is available. Product stability and production efficiency may be increased through the purification process. For example, chromatography or the like can be used, but is not limited thereto, and includes methods commonly used in microbial culture solution purification processes.
  • N-carbamyl-L-glutamic acid which had to be produced by conventional chemical methods, can be biosynthesized by culturing Lactobacillus reuteri strains, and safe physiological activity produced as metabolites by Lactobacillus reuteri strains, which are beneficial intestinal bacteria NCG, a substance, can be efficiently produced.
  • Another aspect of the present invention provides a composition for preventing or treating inflammatory diseases comprising N-carbamyl-L-glutamic acid as an active ingredient.
  • N-carbamyl-L-glutamic acid N-carbamyl-L-glutamic acid, NCG
  • NCG Novel production method of N-carbamyl-L-glutamic acid ”.
  • the term "inflammatory disease” refers to the pathological condition of an abscess formed in the body by bacterial invasion.
  • Inflammatory diseases include, for example, inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, gout, ankylosing spondylitis, tendonitis, and tenosynovitis.
  • rheumatoid fever, lupus, fibromyalgia (fibromyalgia), psoriatic arthritis, asthma, dermatitis may be an acute chronic inflammatory disease, such as atopy, may be specifically inflammatory bowel disease. It is not limited thereto and may include all inflammatory pathological conditions appearing throughout the body.
  • the term "intestine” refers to the region of the digestive tract extending from the stomach to the anus. In humans and other mammals, the intestine consists of two regions: the small intestine (in humans, it is further subdivided into duodenum, empty intestine, and stone intestine) and the large intestine (in humans, it is further subdivided into cecum and colon); It may have a complex intestine, and in the present invention, the intestine may include all of them.
  • the term "inflammatory bowel disease” is a chronic disease of unknown cause in which the intestine becomes inflamed, and collectively refers to all chronic digestive diseases in which intestinal inflammation lasts for several months or more and becomes chronic.
  • the inflammatory bowel disease may be ulcerative colitis, Crohn's disease or Behcet's enteritis. However, regardless of the cause of inflammation, it can include any disease in which abnormal chronic inflammation occurs in the intestine. Ulcerative colitis is characterized by inflammation of the mucous membrane of the large intestine extending from the rectum to the proximal large intestine, and Crohn's disease can occur throughout the gastrointestinal tract from the mouth to the anus.
  • Behcet's disease is an inflammatory disease that chronically manifests in various organs throughout the body. However, it is not limited thereto, and includes all diseases in which abnormal chronic inflammation in the intestinal tract repeats improvement and recurrence. Symptoms of the inflammatory bowel disease include diarrhea, mucous stool, abdominal pain, weight loss, rectal bleeding, anal pain, constipation, abdominal mass, fever, and the like. In addition, symptoms such as increased expression of inflammatory markers and increased expression of carbamyl phosphate synthetase-1 (Cps1) may appear.
  • Cps1 carbamyl phosphate synthetase-1
  • the N-carbamyl-L-glutamic acid has an effect of preventing, improving or treating inflammatory bowel disease.
  • prevention refers to any action that suppresses or delays the onset of a disease or adverse condition by administering a composition to a subject.
  • treatment may be any action that improves the symptoms of a disease or negative condition that has been caused by administering a composition to a subject.
  • the term “improvement” refers to all actions including improvement, suppression, or delay of symptoms, and may be used interchangeably with the prevention or treatment.
  • the N-carbamyl-L-glutamic acid has a therapeutic effect on inflammatory bowel disease.
  • Inflammatory bowel disease treatment is all that improves the negative conditions such as weight loss, occult blood in feces, watery feces, and destruction of the structure of crypts and villi in the intestine, which are representative clinical symptoms of inflammatory bowel disease. It means (FIG. 11b to 11c, FIG. 12, FIG. 13).
  • the N-carbamyl-L-glutamic acid has an activity to reduce the expression of inflammatory markers.
  • the inflammatory markers may be proinflammatory cytokines, inflammation-related enzymes, and infiltration of immune cells.
  • the pro-inflammatory cytokine may be TNF ⁇ , IFN ⁇ , Il-6, Il-8, Il-1 ⁇ , IL-17, etc.
  • the inflammation-related indicator may be iNOs that produce nitric oxide.
  • infiltration of immune cells such as bone marrow cells or macrophages may be reduced.
  • the N-carbamyl-L-glutamic acid has an activity to restore barrier functionality.
  • Restoring the barrier function may mean restoring the intestine to its original state by increasing the surface area of the intestine damaged by inflammation, or reducing damage by protecting the intestine from damage.
  • the restoration of the barrier function may be by increasing the expression of genes or protein markers related to the function or proliferation of the intestinal barrier or the expression of goblet cells and Panes cells in the intestinal mucus layer in the damaged intestine.
  • the barrier function marker is ZO-1 protein or CLDN1 protein, intestinal epithelial structural protein (ECAD), intestinal epithelial cell and structural genes (VIL1, EPCAM, KRT20), barrier structural gene (CLAUDIN), goblet cell marker gene (MUC2) , Panes cell marker gene (LYZ), and the proliferation marker may be barrier proliferation marker Ki67 protein, but is not limited thereto.
  • the N-carbamyl-L-glutamic acid is characterized by activating the Wnt signaling pathway.
  • the Wnt signaling pathway is a pathway that performs various and important functions related to cell proliferation, differentiation, death, migration, and survival within cells, and plays a role in regulating the immune response in cancer or inflammatory diseases, although the exact mechanism has not been elucidated.
  • N-carbamyl-L-glutamic acid can exhibit a therapeutic effect on inflammatory diseases by activating the Wnt signaling pathway and regulating the immune response in inflammatory diseases.
  • genes whose expression is increased may be Fzd7, Tcf7, Ror1, and Axin2.
  • Carbamyl phosphate synthase-1 (Cps1) is the first enzyme involved in the mitochondrial urea cycle. It is mainly expressed in intestinal epithelial cells and hepatocytes. The protein detoxifies ammonia and de novo arginine with other enzymes in the urea cycle. ) serves as a source of supply. It is known that expression of Cps1 is increased in dysplastic tissues of inflammatory bowel diseases such as ulcerative colitis or gastrointestinal cancers.
  • N-carbamyl-L-glutamic acid is a metabolic analogue of N-acetylglutamate that activates Cps1, but N-carbamyl-L-glutamic acid at this concentration does not affect the expression or activity of Cps1 in inflammatory bowel disease. there is.
  • Cps1 whose expression is increased in patients with ulcerative colitis, was confirmed to have no change in expression level when treated with NCG, and therefore, the therapeutic effect of NCG on inflammatory bowel disease is not related to Cps1 was confirmed (Fig. 15h).
  • N-carbamyl-L-glutamic acid is characterized by no toxicity and excellent stability. Since N-carbamyl-L-glutamic acid is produced by the beneficial microorganism Lactobacillus reuteri strain or is chemically identical thereto, it can be stably used as an alternative treatment for existing inflammatory bowel disease without side effects.
  • N-carbamyl-L-glutamic acid is produced by the beneficial microorganism Lactobacillus reuteri strain or is chemically identical thereto, it can be stably used as an alternative treatment for existing inflammatory bowel disease without side effects.
  • histological changes including the length of the large intestine, crypts and villi structures, and significant changes in the expression level of inflammatory markers, barrier function, etc. It was confirmed that there was no toxicity and no side effects (FIGS. 16a to 16f).
  • the preventive, ameliorative, or therapeutic activity of N-carbamyl-L-glutamic acid for inflammatory bowel disease may be increased.
  • 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM may be included in a concentration range selected from the upper limit of any one selected from the group consisting of 500 mM, specifically, 1 mM to 300 mM, 20
  • the therapeutic activity for inflammatory bowel disease with N-carbamyl-L-glutamic acid can be maximized when it is included at 250 mM to 250 mM, 50 mM to 300 mM,
  • NCG 1, 10, 100, 200, 250, 500 mM
  • the composition of the present invention contains N-carbamyl-L-glutamic acid, which has excellent preventive, ameliorative, or therapeutic effects on inflammatory diseases, particularly inflammatory bowel diseases, as an active ingredient, and is a safe ingredient without side effects, thereby treating inflammatory diseases.
  • N-carbamyl-L-glutamic acid which has excellent preventive, ameliorative, or therapeutic effects on inflammatory diseases, particularly inflammatory bowel diseases, as an active ingredient, and is a safe ingredient without side effects, thereby treating inflammatory diseases.
  • the composition may be a pharmaceutical composition, health functional food composition or feed composition.
  • the pharmaceutical composition of the present invention is prepared in unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by those skilled in the art. Or it may be prepared by putting it in a multi-dose container.
  • the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule or gel (eg, hydrogel), and may additionally contain a dispersing agent or stabilizer.
  • a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by those skilled in the art. Or it may be prepared by putting it in a multi-dose container.
  • the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule or gel (eg, hydrogel), and may additionally contain a dispersing agent or stabilize
  • the N-carbamyl-L-glutamic acid contained in the pharmaceutical composition may be incorporated into a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline solution, lipid, liposome, microspheres, or nano-spherical particles.
  • a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline solution, lipid, liposome, microspheres, or nano-spherical particles.
  • pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, poly vinylpyridone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto.
  • lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like may be further included. Suitable pharmaceutically acceptable carriers and agents are described in detail in Remington's Pharmaceutical Sciences, 19th ed., 1995.
  • the pharmaceutical composition can be administered orally or parenterally during clinical administration and can be used in the form of a general pharmaceutical preparation. That is, the pharmaceutical composition of the present invention can be administered in various oral and parenteral formulations at the time of actual clinical administration, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, Or prepared using an excipient.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose in a herbal extract or fermented herbal medicine. , gelatin, etc. are mixed and prepared.
  • Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
  • Witepsol, Macrogol, Tween 61, cacao butter, laurin paper, glycerol, gelatin, and the like may be used as a base for the suppository.
  • the pharmaceutical composition may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention or improvement of inflammatory diseases.
  • the concentration of the active ingredient included in the pharmaceutical composition may be determined in consideration of the purpose of treatment, the condition of the patient, the required period, and the like, and is not limited to a specific range of concentration.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type of patient's disease, severity, activity of the drug, It may be determined according to factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
  • the pharmaceutical composition may be administered as an individual therapeutic agent, or may be administered in combination with other therapeutic agents for intestinal developmental disorders, may be administered simultaneously, separately, or sequentially with conventional therapeutic agents, and may be administered single or multiple times. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors, which can be easily determined by those skilled in the art.
  • N-carbamyl-L-glutamic acid contained in the pharmaceutical composition of the present invention is administered to a patient at an appropriate concentration, the preventive, ameliorative, or therapeutic effect of N-carbamyl-L-glutamic acid on inflammatory bowel disease is maximized.
  • NCG per 25 g of body weight is selected from the group consisting of 1 mM, 5 mM, 10 mM, 20 mM, 30 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM and 100 mM N-carbamyl-L-glutamic acid.
  • the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, body weight, absorption of the active ingredient in the body, inactivation rate, excretion rate, disease type, concomitant drug, administration route, obesity It may increase or decrease according to severity, gender, weight, age, etc.
  • it may be administered several times a day at regular time intervals, for example, 2 to 3 times a day.
  • Another aspect of the present invention provides a kit comprising the pharmaceutical composition.
  • a pharmaceutical composition for treating inflammatory diseases by administering a therapeutically effective amount of N-carbamyl-L-glutamic acid, and (2) 0.001 mM to 0.001 mM to 25 g of N-carbamyl-L-glutamic acid per 25 g of patient weight.
  • a kit including a package insert instructing administration at a concentration of 300 mM is provided.
  • the formulation of the pharmaceutical composition, administration method, dosage and description of the concentration of the active ingredient contained in the composition are the same as those described above.
  • the packaging insert contains instructions for the dosage described above.
  • the kit of the present invention may be attached with a packaging insert having instructions such as precautions in the form instructed by a government agency regulating the manufacture, use, or sale of drugs or biological products.
  • Another aspect of the present invention provides a method for preventing or treating an inflammatory disease comprising administering the pharmaceutical composition to a subject.
  • the subject may be a human or a non-human animal, and the subject may be a human or non-human animal in an early or middle stage of an inflammatory disease, particularly an inflammatory bowel disease.
  • composition The formulation of the pharmaceutical composition, administration method, dosage and description of the concentration of the active ingredient contained in the composition are the same as those described above.
  • the health functional food composition of the present invention can prevent or improve inflammatory diseases of humans or non-human animals.
  • the health functional food composition When using the health functional food composition as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods.
  • the amount of the active ingredient can be appropriately used depending on the purpose of its use (prevention or improvement).
  • the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material.
  • the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • Foods to which the health functional food composition can be added may be probiotics preparations, such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, and various
  • probiotics preparations such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, and various
  • soups, beverages, tea drinks, alcoholic beverages, vitamin complexes, and fermented foods and includes all health foods in a conventional sense.
  • the fermented food may be yogurt (hard type, soft type, drink type), fermented milk such as lactic acid bacteria beverage, cheese or butter, but is not limited thereto, and any fermented microorganisms or lactic acid bacteria are produced by fermentation. It can include food and even products.
  • the health functional food composition may be prepared as a food, particularly a functional food.
  • the functional food includes ingredients commonly added during food preparation, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
  • natural carbohydrates or flavoring agents may be included as additional ingredients in addition to active ingredients.
  • the natural carbohydrates are monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrins, cyclodextrins, etc.) or sugar alcohols (eg, maltose, sucrose, etc.) , xylitol, sorbitol, erythritol, etc.) are preferred.
  • natural flavoring agents eg, thaumatin, stevia extract, etc.
  • synthetic flavoring agents eg, saccharin, aspartame, etc.
  • the ratio of the components to be added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition.
  • the feed composition of the present invention can prevent or improve inflammatory diseases in animals other than humans, and can be added as a feed additive composition for this purpose.
  • the feed additives correspond to supplementary feeds under the Feed Management Act.
  • the term "feed” means any natural or artificial diet, one meal, etc., or a component of the one meal for an animal to eat, ingest, and digest, or suitable therefor, and the animal is an animal other than a human.
  • the type of feed is not particularly limited, and feeds commonly used in the art may be used.
  • Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal or grain by-products; Animal feed such as proteins, inorganic materials, oils, mineral oils, oils, single cell proteins, zooplankton, or food may be mentioned. These may be used alone or in combination of two or more.
  • Intestinal organoids were prepared by differentiating human pluripotent stem cells.
  • human pluripotent stem cells For the differentiation of human pluripotent stem cells, a method known in the art (Nature 470, 105-109 (2011)) was used. Specifically, for the induction of true endoderm in human pluripotent stem cells (H9 (WA09); WiCell Research Institute, Madison, WI, USA), fetal bovine serum for 3 days with 100 ng/ml of Activin A (FBS, Thermo Scientific)) was treated with the stem cells, and the fetal bovine serum was treated while increasing the concentration to 0%, 0.2%, and 2%, respectively.
  • FBS Activin A
  • fetal bovine serum 500 ng/ml of FGF4, 3 ⁇ M of CHIR 99021, and 2% fetal bovine serum were additionally cultured for 4 days using a differentiation medium.
  • Spheroids formed by induction of differentiation are inserted into the dome of Matrigel, and in a three-dimensional culture environment, 1 ⁇ B27 supplement (B27 supplement, Invitrogen), 100 ng/ml EGF (R&D Systems), 100 ng/ml Noggin (R&D Systems ), and cultured in a culture medium containing 500 ng/ml R-spondin1 (R-spondin1, R&D Systems), and subcultured once every 10 days and used for experiments.
  • the intestinal organoids differentiated according to Example [1-1] were treated with several species of lactic acid bacteria and the same strain of Lactobacillus reuteri, and the maturation of the intestinal organoids was confirmed.
  • Lactic acid bacteria used were Bifidobacterium longum DS0431 (B. longum DS0431, isolated from feces of newborns), Lactobacillus gasseri DS0444 (L. gasseri DS0444, isolated from breast milk), Lactobacillus curvatus AB70 (L. curvatus AB70, female isolated from genital organs), Lactobacillus rhamnosus DS0979 (L.
  • Lactobacillus reuteri DS0384 L. reuteri DS0384, isolated from newborn feces strains of the present invention were used.
  • the culture solution of the five microbial strains cultured was centrifuged at 12,000 rpm for 10 minutes using a centrifuge, and only the supernatant was collected.
  • the collected supernatant was pasteurized for 30 minutes on a heat block preheated to 65 ° C., and impurities were removed by filtering with a 0.22 ⁇ m syringe filter unit.
  • the culture solution isolated in this way was treated by diluting 1/100 in the culture medium of the intestinal organoid, and subcultured twice for a total of 20 days, and changes in the intestinal organoid were observed.
  • the morphological changes of the intestinal organoids were confirmed by checking the size change of the intestinal organoids and the number of budding structures. Specifically, the size of 6 organoids for each lactic acid bacteria treatment group was measured and compared through photographs taken by observing intestinal organoids under a microscope, and the number of budding structures was 6 organoids for each lactic acid bacteria treatment group. For each organoid, the number of budding structures generated was confirmed.
  • OLFM4 a mature intestinal stem cell marker, DEFA5, a mature Paneth cell marker, KRT20, a mature intestinal structural protein marker, and MUC13, a mucus-producing cell marker, were targeted as marker proteins.
  • intestinal organoids treated with 5 types of lactic acid bacteria cultures as described above were fixed in 4% PFA (paraformaldehyde), cryoprotected with 10-30% sucrose solution, treated with OCT solution, and frozen.
  • the frozen intestinal organoid tissue was cut into 10-20 ⁇ m thick slices with a microtome, treated with PBS containing 0.1% Triton X-100, permeabilized through the slices, and then treated with 4% bovine serum (BSA). It was blocked for 1 hour with PBS containing albumin).
  • Anti-OLFM4 antibody (ab85046, abcam, Cambridge, MA, USA), anti-DEFA5 antibody (ab90802, abcam), anti-KRT20 antibody (ab76126, abcam) and anti- MUC13 antibody (ab124654, abcam) was diluted at 1:100 and reacted overnight at 4°C, followed by secondary antibody, anti-goat IgG Alexa Fluor 488, A21467, Invitrogen, anti- Rabbit antibody (anti-rabbit IgG Alexa Fluor 594, A21442, Invitrogen) and anti-mouse antibody (anti-mouse IgG Alexa Fluor 594, A21203, Invitrogen) were diluted 1:200 each and reacted at room temperature for 1 hour to obtain DAPI After staining the nuclei with staining, they were observed under a fluorescence microscope.
  • the Lactobacillus reuteri DS0384 strain of the present invention exhibits intestinal effects when treated with human intestinal organoids. It was confirmed to significantly increase the expression of genes and proteins related to maturation, and it can be seen that it actually promotes intestinal development and maturation, such as increasing the size of intestinal organoids and inducing the formation of germination structures. .
  • Example [1-2] it was confirmed that the Lactobacillus reuteri DS0384 strain was superior in promoting intestinal maturation and development compared to lactic acid bacteria belonging to other species. Accordingly, the DS0384 strain of the present invention was compared with other strains classified as the same species, and the difference in the maturation promoting effect of intestinal organoids was compared and tested.
  • the effects of treating the intestinal organoid with cultures of DS0191, DS0195, DS0333, and DS0354 strains and treating the DS0384 strain culture solution compared with Experiments were conducted using the same method as in Example [1-2], and morphological changes of intestinal organoids were confirmed after treatment with the culture medium, and the expression levels of proteins and genes used as mature intestinal markers were measured by immunofluorescence staining and qRT. -Confirmed through PCR.
  • the DEFA5 gene is a gene encoding DEFA5 (Defensin alpha 5) protein, which is abundantly present on the surface of the intestine, and is expressed at a high level in mature Paneth cells, and thus is used as a marker. Therefore, the DS0384 strain of the present invention, which exhibits an increased expression level of the OLFM4 gene and the DEFA5 gene, unlike other microbial strain culture solution treatment groups, can promote intestinal maturation and development in a different way than other strains, thereby promoting maturation It was confirmed that the effect appeared more markedly.
  • the present invention DS0384 strain culture medium-treated group showed conspicuous maturation of intestinal organoids, and immunofluorescence
  • the expression of OLFM4, DEFA5, KRT20 and MUC13 proteins was found only in the DS0384 strain culture solution treatment group (Fig. 3a).
  • the expression of 10 mature intestinal marker genes was significantly increased in the DS0384 strain culture medium-treated group compared to the control group, whereas the expression levels in the other 3 reuteri strain-treated groups were significantly increased compared to the control group. It was found that it appeared significantly less than the treatment group and even less than the control group (FIG. 3 b).
  • the lactic acid bacteria strains classified as other species from Reuteri did not show the effect of promoting intestinal maturation
  • the DS0384 strain showed an effect of promoting intestinal maturation compared to the culture solution treatment groups of other strains belonging to Lactobacillus reuteri. It was found to be remarkably excellent, and it was found that the culture medium of strain Lactobacillus reuteri DS0384 had a specific active component related to intestinal maturation or intestinal development.
  • the intestinal maturation promoting effect was confirmed in the culture medium obtained by varying the culture time in the same manner as in Example [1-2].
  • the intestinal organoids were treated using the culture solution obtained for each time, and the morphological change of the intestinal organoids and Together, the expression levels of 10 intestinal maturation marker genes including the CDX2 gene were measured by qRT-PCR in the same manner as in Example [1-2].
  • Metabolome analysis of the culture solution of the Lactobacillus reuteri DS0384 strain was performed using capillary electrophoresis mass spectrometry (CE-TOFMS). Specifically, to perform ionic metabolomic analysis, 80 ⁇ L of culture supernatant of strains Lactobacillus reuteri DS0384, KCTC3594 and DS0195 was mixed with 20 ⁇ L of Mili-Q-water containing an internal standard (1 mM), followed by the manufacturer's instructions. Capillary electrophoretic mass spectrometry was performed according to
  • Example [1-5] In order to identify physiologically active metabolites related to intestinal maturation or development, through the metabolomic analysis of Example [1-5], differential among 14 metabolites contained more in the culture medium of DS0384 compared to the culture medium of other Reuteri strains. After selecting 7 components that were abundantly contained in the intestinal organoids and treating them, the maturation of the intestinal organoids was confirmed.
  • Example [1-2] The same method as in Example [1-2] using 7 metabolites (succinic acid, histidine, xanthine, CMP, 6-ACA, NCG, and SCMC) included in differentially high amounts among the 14 metabolites As a result, it was confirmed that the intestinal organoid has an effect of promoting intestinal maturation and intestinal development.
  • 7 metabolites succinic acid, histidine, xanthine, CMP, 6-ACA, NCG, and SCMC
  • each metabolite-treated organoid was cut into 10 ⁇ m sections to prepare a sample, and the marker proteins in the sample were OLFM4, a mature intestinal stem cell marker, and mature Samples were treated with primary antibodies targeting DEFA5, a Paneth cell marker, KRT20, a mature intestinal structural protein marker, and MUC13, a mucus-producing cell marker, and incubated overnight at 4°C. Thereafter, the secondary antibody was treated and reacted at room temperature for 1 hour, and the nuclei were stained with DAPI staining and observed under a fluorescence microscope.
  • N-carbamyl-L-glutamic acid N-carbamyl-L-glutamic acid
  • FIGS. 7 and 8 NCG exhibited the highest level of intestinal development and maturation, similar to the experimental group treated with the culture medium.
  • pro-inflammatory cytokines 125 ng/ml IFN ⁇ and 125 ng/ml TNF ⁇
  • pro-inflammatory cytokines 125 ng/ml IFN ⁇ and 125 ng/ml TNF ⁇
  • Pro-inflammatory cytokines and NCG were simultaneously treated to confirm whether NCG has an intestinal protective effect against inflammation. Morphological changes were observed in normal intestinal organoids, colitis intestinal organoids, and 1 mM NCG-treated intestinal organoids in the same manner as in Example 3, and intestinal functional changes were confirmed through histological changes and mucin staining. Immunofluorescent staining was performed to confirm barrier functionality (ZO-1) and intestinal stem cell proliferation (Ki-67), followed by fluorescence microscopy.
  • Indicators of inflammation such as IL-1 ⁇ , IL-6, IL-8, and TNF ⁇ , and intestinal epithelial structure (VIL1, EPCAM, KRT20), barrier function (CLAUDIN), intestinal goblet cells (MUC2), Panes cells (LYZ)
  • VIL1 intestinal epithelial structure
  • EPCAM EPCAM
  • KRT20 barrier function
  • CLAUDIN barrier function
  • MUC2 intestinal goblet cells
  • LYZ panes cells
  • the experiment was conducted by classifying 5-7 week old, 20-25 g (more than 20 g) male C57BL/6J mice (DBL, Eumseong, Korea) into a normal group, a control group, and an experimental group.
  • the normal group was a group without any treatment, and ulcerative colitis was induced in the control and experimental groups by mixing 2 to 2.5% DSS in drinking water.
  • mice that exceed the lower limit of standard deviation more than twice were excluded from the analysis.
  • Mice that rapidly induced early symptoms (mice that fell outside the lower limit of standard deviation more than twice) belonged to the group that should be mostly excluded from the IACUC criteria (humane measures for mice with weight loss of 20% or more). Additionally, since mice that deviate from the standard deviation during the initial DSS-induced symptomatic period (days 4 to 6) cause large intra-group variability.
  • Mature functional goblet cells were observed in intestinal organoids and animal model intestinal tissues using an AB-PAS staining technique that stains mucin secreted from mature goblet cells. Tissue sections having a thickness of 10 ⁇ m prepared as described above were adhered to slide glass, and then stained using the Alcian Blue PAS Stain Kit. Thereafter, dehydration was performed by passing through ethanol (Ethanol) by concentration, and then washed and sealed using xylene. Mucin mucin was observed in intestinal tissue using an optical microscope (BX53F, Olympus, Japan).
  • Example [3-1] a tissue specimen prepared in the same manner as in Example [3-1] was adhered to a slide, and then permeabilized with PBS containing 0.1% Triton X-100 for immunofluorescence staining. After washing three times with PBS containing Tween 20, blocking with 4% BSA, the tissue was reacted with the primary antibody overnight at 4°C. Thereafter, the secondary antibody was reacted for 1 hour at room temperature. Primary antibodies used are shown in Table 3 below. DAPI was added to visualize the nucleus. The slides were observed under an EVOS FL Auto2 (ThermoFisher) and Axiovert 200M microscope (Carl Zeiss, Gottingen, Germany) or a fluorescence microscope (IX51, Olympus, Japan).
  • EVOS FL Auto2 ThermoFisher
  • Axiovert 200M microscope Carl Zeiss, Gottingen, Germany
  • fluorescence microscope IX51, Olympus, Japan
  • RNA samples were prepared with an RNA Integrity Number (RIN) of 7.5 or higher using the Agilent 2100 Bioanalyzer system (Agilent Biotechnologies, Palo Alto, USA).
  • the mRNA library was prepared using the Illumina TruSeq kit, and sequencing was performed using Illumina HiSeq2500 machines (Illumina, San Diego, CA, USA). Sequencing quality was determined using the FastQC package, and read lengths of 50 bases or less were excluded. After that, mapping was performed through HISAT2 (v2.0.5), and human genome information used hg19. Differentially expressed genes (DEGs) were analyzed between samples using Cuffquant and Cuffnorm (Cufflinks v2.2.1).
  • DEGs Differentially expressed genes
  • Bioinformatic analysis was performed using IPA analysis software (Ingenuity systems, Redwood City, CA, USA), PANTHER (Protein ANalysis Through Evolutionary Relationships, http://www.pantherdb.org) database, and DAVID Bioinformatics Resource 6.7 (http://www.pantherdb.org). david.abcc.ncifcrf.gov). Hierarchical clustering and heat map analysis was performed using MeV v 4.9.0 software.
  • Example [2-1] intestinal organoids were simultaneously treated with IFN ⁇ /TNF ⁇ and NCG for 3 days, and the intestinal protective effect of NCG against inflammation was observed. And, as described in Example 3 above, mucin secretion and goblet cells, one of the main functions of the intestine, were subjected to mucin mucin staining techniques (AB-PAS staining) and MUC2 immunofluorescence analysis. Proinflammatory cytokines (IL-1 ⁇ , IL-6, IL-8 and Tnf ⁇ ) and intestinal epithelial cells and structures (VIL1, EPCAM, KRT20), barrier structure (CLAUDIN), and goblet cells by qRT-PCR analysis at the gene level (MUC2) and Panes cells (LYZ) were compared.
  • IL-1 ⁇ , IL-6, IL-8 and Tnf ⁇ Proinflammatory cytokines
  • VIL1, EPCAM, KRT20 intestinal epithelial cells and structures
  • CLAUDIN barrier structure
  • goblet cells by qRT-PCR analysis at the
  • barrier functionality (ZO-1) was restored, cells expressing the intestinal stem cell proliferation marker (ki-67) were not reduced, and intestinal epithelial structure (ECAD) was improved. Compared to the marker, the expression level of the barrier structure (ZO-1) increased (FIG. 9e).
  • cytokines such as IL-1 ⁇ , IL-6, IL-8, and TNF ⁇ was increased, but concurrent treatment with NCG increased inflammation.
  • the expression of cytokines decreased, and the expression of intestinal epithelial cells and structures (VIL1, EPCAM, KRT20), barrier structure (CLAUDIN), goblet cells (MUC2), and Panes cells (LYZ) increased (FIG. 9f ),
  • NCG has an effect of protecting the intestine against colitis.
  • ulcerative colitis was evaluated in an animal model in which NCG was orally administered.
  • the experimental group was orally administered 200 ⁇ l of NCG at different concentrations (0, 1, 10, 100, 200, 250, 500 mM) daily while treating drinking water for 8 days. After that, colitis was induced with 2% DSS drinking water for 7 days, and NCG was also orally administered for 7 days (FIG. 10a).
  • the control group was treated with DSS and then injected intraperitoneally with PBS. Thereafter, according to the method described in Examples 2 and 3, weight gain and loss, fecal morphology, and occult blood in feces, which are important indicators of intestinal inflammatory disease, were observed for a total of 15 days.
  • ulcerative colitis was evaluated by orally administering NCG to an animal model of ulcerative colitis.
  • Example 2 After inducing colitis by administering 2-2.5% DSS drinking water to the mice prepared in Example 2 for 8 days, DSS drinking was stopped and drinking water was administered for 7 days.
  • the experimental group was orally administered 200 ⁇ l of NCG daily for 10 days at various concentrations (0, 10, 50, 100, 200, 500 mM) from the 5th day, when the weight gain rate inflection point, soft stools and diarrhea, which are the initial symptoms of ulcerative colitis, were observed.
  • a control group received an intraperitoneal injection of PBS (FIG. 11A).
  • NCG exhibits a therapeutic effect on ulcerative colitis, and an appropriate dosage range of NCG capable of exhibiting a therapeutic effect is 100 to 200 mM.
  • NCG has an effect of restoring the function of the intestinal wall in an ulcerative colitis model.
  • mucin secretion and goblet cells one of the main functions of the intestine, were subjected to mucin mucin staining technique (AB-PAS staining) and MUC2 immunofluorescence analysis.
  • FIG. 13 it was confirmed through immunofluorescence staining that the expression of barrier function-related proteins (ZO-1, CLDN1) and intestinal epithelial structural protein (ECAD) increased, and the intestinal structure was significantly recovered compared to the control group. confirmed that it was.
  • ZO-1, CLDN1 barrier function-related proteins
  • ECAD intestinal epithelial structural protein
  • intestinal proinflammatory cytokines at the protein or gene level, secretion of inflammation-related enzymes and infiltration of immune cells phenomenon was observed.
  • the secretion of pro-inflammatory cytokines (TNF ⁇ , IFN ⁇ , IL-17), inflammation-related enzymes (iNOS), and infiltration of immune cells (myeloid cells; CD11b+, macrophages; F4/80+) were analyzed by immunofluorescence staining.
  • Expression levels of pro-inflammatory cytokines Il-6, Il-1 ⁇ , Tnf ⁇ , Il-17a
  • nitric oxide indicator iNos were measured by qPCR analysis at the gene level.
  • RNAseq-based genome analysis was performed on the normal group, the colitis control group, and the 100 and 200 mM NCG treated experimental groups.
  • NCG does not affect the expression of Cps1, activates the Wnt signaling pathway or increases the expression of Ki-67, thereby promoting the proliferation of intestinal stem cells. , it can be seen that it can show the therapeutic effect of ulcerative colitis through this.
  • PBS or NCG was orally administered to mice of the normal group for 10 days from the 5th day of drinking water, and clinical symptoms were observed for 10 days (FIG. 16a).
  • the 100mM NCG treated group showed a greater increase in body weight than the normal group, but there was no significant difference except for the 9th day (FIG. 16b).
  • the shape of the feces was similar to that of the control group in the form of lumps, confirming that there was no toxicity (FIG. 16c).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de biosynthèse de l'acide N-carbamyl-L-glutamique et une nouvelle utilisation de celui-ci pour la prévention ou le traitement de maladies inflammatoires. L'invention concerne également une composition pour la prévention, l'amélioration ou le traitement des maladies inflammatoires de l'intestin, qui contient de l'acide N-carbamyl-L-glutamique en tant que principe actif, ce qui permet de minimiser les effets secondaires des traitements existants pour les maladies inflammatoires de l'intestin et d'en assurer la stabilité.
PCT/KR2023/002981 2022-03-03 2023-03-03 Composition contenant de l'acide n-carbamyl-l-glutamique pour le traitement de maladies inflammatoires WO2023167563A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0027575 2022-03-03
KR20220027575 2022-03-03

Publications (1)

Publication Number Publication Date
WO2023167563A1 true WO2023167563A1 (fr) 2023-09-07

Family

ID=87884071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/002981 WO2023167563A1 (fr) 2022-03-03 2023-03-03 Composition contenant de l'acide n-carbamyl-l-glutamique pour le traitement de maladies inflammatoires

Country Status (2)

Country Link
KR (1) KR20230131450A (fr)
WO (1) WO2023167563A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055082A1 (en) * 2008-09-04 2010-03-04 Jacques Alain Bauer Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
KR20110019058A (ko) * 2009-08-19 2011-02-25 인하대학교 산학협력단 락토바실러스 루테리로부터 분리 정제된 글루타미나제 및 이의 정제 방법
KR20110051268A (ko) * 2008-09-04 2011-05-17 오엠 파르마 락토바실러스 박테리아 유래 면역조절 추출물 및 이의 제조 방법 및 이의 용도
KR20150027152A (ko) * 2012-05-29 2015-03-11 다누타 크루셰프스카 인간 및 동물 모두에서 예방 및 의약에 유용한 락토바실러스 류테리 ｄａｎ080을 포함하는 나노프로덕트 및 이의 의학적 용도
KR20210158357A (ko) * 2020-06-23 2021-12-30 한국생명공학연구원 신규 락토바실러스 루테리 균주 및 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055082A1 (en) * 2008-09-04 2010-03-04 Jacques Alain Bauer Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
KR20110051268A (ko) * 2008-09-04 2011-05-17 오엠 파르마 락토바실러스 박테리아 유래 면역조절 추출물 및 이의 제조 방법 및 이의 용도
KR20110019058A (ko) * 2009-08-19 2011-02-25 인하대학교 산학협력단 락토바실러스 루테리로부터 분리 정제된 글루타미나제 및 이의 정제 방법
KR20150027152A (ko) * 2012-05-29 2015-03-11 다누타 크루셰프스카 인간 및 동물 모두에서 예방 및 의약에 유용한 락토바실러스 류테리 ｄａｎ080을 포함하는 나노프로덕트 및 이의 의학적 용도
KR20210158357A (ko) * 2020-06-23 2021-12-30 한국생명공학연구원 신규 락토바실러스 루테리 균주 및 이의 용도

Also Published As

Publication number Publication date
KR20230131450A (ko) 2023-09-13

Similar Documents

Publication Publication Date Title
AU2020336649B2 (en) Akkermansia muciniphila EB-AMDK19 strainand use thereof
WO2019216662A1 (fr) Souche de lactobacillus paracasei et utilisation associée
WO2017074037A1 (fr) Nouvelle souche dérivée d'aliments fermentés traditionnels et présentant une excellente productivité enzymatique, et procédé de préparation d'aliments fermentés enzymatiques à base de céréales à l'aide de ladite souche
AU2020339348B2 (en) Akkermansia muciniphila EB-AMDK27 strain and use thereof
WO2019226015A1 (fr) Composition pour favoriser la myogenèse, contenant un extrait de ginseng traité
WO2019226002A1 (fr) Souche de lactobacillus crispatus kbl693 et utilisation associée
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
WO2021066549A1 (fr) Souche de lactobacillus acidophilus kbl409 et son utilisation
WO2016093599A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie métabolique, comprenant des bactéries bacteroides acidifaciens utilisées comme principe actif efficace
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
WO2021230581A1 (fr) Découverte d'une nouvelle akkermansia muciniphila ak32 et application correspondante pour la prévention ou le traitement d'une lésion intestinale
WO2021251575A1 (fr) Nouvelle souche de pediococcus pentosaceus et composition alimentaire pour la prévention ou l'amélioration de l'obésité ou d'une stéatose hépatique comprenant un produit fermenté à base de lactosérum associé
WO2023167563A1 (fr) Composition contenant de l'acide n-carbamyl-l-glutamique pour le traitement de maladies inflammatoires
WO2020226467A1 (fr) Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation
WO2020226438A1 (fr) Peptide pour la prévention ou le traitement de maladies intestinales inflammatoires
WO2023113541A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer ou d'une maladie inflammatoire
WO2023068855A1 (fr) Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse
WO2023058801A1 (fr) Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409
WO2021261929A1 (fr) Nouvelle souche de lactobacillus reuteri et utilisation associée
WO2022039514A1 (fr) Composition pour le traitement de maladies cérébrales comprenant lactobacillus sakei ou des vésicules extracellulaires dérivées de celui-ci en tant que principe actif
WO2022015033A1 (fr) Composition pour le traitement d'une maladie cérébrale comprenant pediococcus inopinatus ou des vésicules extracellulaires dérivées de celui-ci en tant que substance active
WO2017196140A2 (fr) Additif alimentaire pour animaux d'aquaculture comprenant la souche bfe920 de lactococcus lactis induisant des lymphocytes t immunomodulateurs
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2023080553A1 (fr) Peptide ayant une activité physiologique et son utilisation
WO2023080552A1 (fr) Peptide ayant des activités physiologiques et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23763761

Country of ref document: EP

Kind code of ref document: A1